reference/35247428

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/35247428

Outgoing Links

Predicate	Object
contentType	Multicenter Study\|Journal Article
endingPage	2149
issn	1432-0851 0340-7004
issueIdentifier	7
pageRange	2137-2149
publicationName	Cancer immunology, immunotherapy : CII
startingPage	2137
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_487baf6554eb36bb22c6138d90a7c50f http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_5664d76c11eaf1a6e77bc3fdb8174ab0 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_78d426517100b185dd076df28453d27d http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_1c0aa062611518a12552a116a65f748d
bibliographicCitation	Li T, Guo J, Liu Y, Du Z, Guo Z, Fan Y, Cheng L, Zhang Y, Gao X, Zhao Y, He X, Wu W, Gao N, Wu Y, Li J, Zhang Y, Kang W, Cai Z, Wang W, Li X, Zan Y, Nguyen MH, Ji F. Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC. Cancer Immunol Immunother. 2023 Feb 25;72(7):2137–49. doi: 10.1007/s00262-023-03404-8.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b03d98a164b6e4b3c4e5974ab6061875 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a833ce6b6d1404fa35b68f2328deb664 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3aa30c575b9974b5c0d3c5b1cd930bcf http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-6275-4989 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f798dabdcaec5475de1a5f42c8709e8f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4f29941cf138848bf1d0f04696a784ac http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4b994009d98da78eb993b1fb1f32b6d1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_860107a51ff4eac9aa47e6142efaed3d http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-1463-8035 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_34060b1153e676bce8ec146d28e8b208 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8e6ca4ad1fd36f6fac43e8af7f616b81 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_01d2e62b008048ed7e65221103f46f3f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f2554cc17f59fdc2cce439d784395dff http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b9e453e0e32ef25e13c459420dca2244 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f4739a161587ec0802c5b0941b93d052 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e1bcbcc3b8f7e01574641ebdac73998c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6712d6f0e84ccdd709c16459c0a15a9e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_655674dab40f0561dbd88a3907f7eb76 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_688e9b1bde14723b8466708f9948538e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_248bf9c45d5d123dc665ed3fd84bea07 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5f7b8759c6fd560b22e9f0103520d7ed http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ced3fe70a0cadd95e8cc86d377883e20 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ea503fa147b44653c82a67272df92cd9
date	2023-02-25^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/36840762 https://pubmed.ncbi.nlm.nih.gov/PMC10264531 https://doi.org/10.1007/s00262-023-03404-8
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2781 https://portal.issn.org/resource/ISSN/0340-7004 https://portal.issn.org/resource/ISSN/1432-0851
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC
discusses	http://id.nlm.nih.gov/mesh/M000651317
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D008113Q000473 http://id.nlm.nih.gov/mesh/D006528Q000473
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D058990 http://id.nlm.nih.gov/mesh/D015331 http://id.nlm.nih.gov/mesh/D006801
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_95d926625e5919a35cb6aa367ba7b069 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11167 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fadc3c8509db129e10ef4cfccf6efc5d http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9887 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7998

Showing number of triples: 1 to 60 of 60.